Therapeutic Efficacy of Interferon Alfa-2b in Infants With Life-Threatening Giant Hemangiomas

Archives of Dermatology

Volumn 133, Issue 12, 1997, Pages 1567-1571

  Tamayo, Lourdes ^a   Ortiz, Dulce M ^a   Orozco Covarrubias, Luz ^a   Durán Mckinster, Carola ^a   Mora, Maria Antonieta ^a   Avila, Estrella ^a   Teixeira, Fernanda ^a   Ruiz Maldonado, Ramón ^a  

^a HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ARTICLE; ARTIFICIAL EMBOLISM; BENIGN TUMOR; CARBON DIOXIDE LASER; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HEMANGIOMA; HUMAN; INFANT; MALE; PRIORITY JOURNAL; REMISSION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; DRUG EVALUATION; EYELID NEOPLASMS; FACIAL NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HEMANGIOMA; HUMANS; INFANT; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; MALE; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TIME FACTORS;

EID: 14444272982     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1997.03890480087013     Document Type: Article

References (31)

1. Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics. 1976;58:218-222.
2. Amir J, Metzker A, Krikler R, Reisner SH. Strawberry hemangioma in preterm infants. Pediatr Dermatol. 1986;3:331-332.
3. Bowers RE, Graham EA, Tomlinson KM. The natural history of the strawberry nevus. Arch Dermatol. 1960;82:667-680.
4. Deans RM, Harris GJ, Kivlin JD. Surgical dissection of capillary hemangioma: an alternative to intralesional corticosteroids. Arch Ophthalmol. 1992;110:1743-1747.
5. Esterly NB. Cutaneous hemangiomas, vascular stains and malformations, and associated syndromes. Curr Probl Pediatr. 1996;26:31.
6. Apfelberg DB, Maser MR, Lash H, et al. Benefits of the CO2 laser in oral hemangioma excision. Plast Reconstr Surg. 1985;75:46-50.
7. David TJ, Evans DIK, Stevens RF. Haemangioma with thrombocytopenia (Kasabach-Merritt syndrome). Arch Dis Child. 1983;58:1022-1023.
8. de Prost Y, Teillac D, Bodemer C, et al. Successful treatment of Kasabach-Merritt syndrome with pentoxifylline. J Am Acad Dermatol. 1991;25:854-855.
9. Nelson LB, Melick JE, Harley RD. Intralesional corticosteroid injections for infantile hemangiomas of the eyelid. Pediatrics. 1984;74:241-245.
10. Enjolras O, Mulliken JB. The current management of vascular birthmarks. Pediatr Dermatol. 1993;10:311-333.
11. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326:1456-1463.
12. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science. 1980; 208:516-518.
13. Friesel R, Komoriya A, MacKay T. Inhibition of endothelial cell proliferation by gamma interferon. J Cell Biol. 1987;104:689-699.
14. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med. 1989; 320:1197-1200.
15. Orchard PJ, Smith CM III, Woods WG, Day DL, Dehner LP, Shapiro R. Treatment of hemangioendotheliomas with alpha interferon. Lancet. 1989;2:565-567.
16. Deb G, Donfrancesco A, De Sio L, Standoli L. Treatment of hemangiomas of infants and babies with interferon alfa-2a: preliminary results. Int J Pediatr Hematol Oncol. 1996;3:109-113.
17. Teillac-Hamel D, De Prost Y, Bodemer C, et al. Serious childhood angiomas: unsuccessful alpha-2b interferon treatment: a report of four cases. Br J Dermatol. 1993;129:473-476.
18. Mulliken JB. Diagnosis and natural history of hemangiomas. In: Mulliken JB, Young AE, eds. Vascular Birthmarks: Hemangiomas and Malformations. Philadelphia, Pa: WB Saunders Co; 1988:41-62.
19. Enjolras O, Riche MC, Merland JJ, Escande JP. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics. 1990;85:491-498.
20. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 1995; 333:1757-1763.
21. Cirelli R, Tyring SK. Major therapeutic uses of interferons. Clin Immunother. 1995; 3:27-87.
22. Voest EE. Angiogenesis and hemangioma. In: Programme Syllabus of the Hemangiomas, Vascular Malformations Symposium and Workshop; November 25-26, 1996; Nijmegen, the Netherlands. Page 31.
23. White CW, Wolf SJ, Korones DN, Sondheimer HM, Tosi MF, Yu A. Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. J Pediatr. 1991;118:59-66.
24. Averbuch SD, Austin HA, Sherwin SA, et al. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte interferon therapy for mycosis fungoides. N Engl J Med. 1984;310:32-35.
25. Horowitz R, Glicklich D, Sablay LB, Wiernik PH, Wadler S. Interferon-induced acute renal failure: a case report and literature review. Med Oncol. 1995;12:55-57.
26. Blei F, Orlow SJ, Geronemus RG. Supraumbilical midabdominal raphe, sternal atresia, and hemangioma in an infant: response of hemangioma to laser and interferon alfa-2a. Pediatr Dermatol. 1993;10:71-76.
27. Loughnan MS, Elder J, Kemp A. Treatment of massive orbital-capillary hemangioma with interferon alfa-2b: short-term results. Arch Ophthalmol. 1992;110: 1366-1367.
28. Quesada JR. Toxicity and side effects of interferons. In: Baron S, Coppenhaver DH, Dianzani F, et al, eds. Interferon: Principles and Medical Applications. Galveston: The University of Texas Medical Branch at Galveston, Dept of Microbiology; 1992:427-432.
29. Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA. 1984;252:938-941.
30. Enjolras O, Pouplard F, Beucher A, Ginies JL, Verret JL. Toxicité neurologique de l'interferon alpha 2a au cours du traitement d'un hemangiome cephalique grave. Ann Dermatol Venereol. 1996;123(suppl l):S144-S145.
31. Marimsky O, Chaitchik S. Neurotoxicity of interferon alpha. Anticancer Drugs. 1992;3:567-570.